We are live on ! Find out more
MWNA

Marshall Wace North America Portfolio holdings

AUM $23.5B
1-Year Est. Return 46.46%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.1B
AUM Growth
+$1.98B
Cap. Flow
+$1.34B
Cap. Flow %
8.3%
Top 10 Hldgs %
18.52%
Holding
1,899
New
351
Increased
456
Reduced
282
Closed
805

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$260M
2
BABA icon
Alibaba
BABA
+$229M
3
GILD icon
Gilead Sciences
GILD
+$168M
4
BA icon
Boeing
BA
+$151M
5
ABT icon
Abbott
ABT
+$148M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$306M
2
UNH icon
UnitedHealth
UNH
+$244M
3
VMC icon
Vulcan Materials
VMC
+$146M
4
PEP icon
PepsiCo
PEP
+$98.4M
5
ELV icon
Elevance Health
ELV
+$96.5M

Sector Composition

Rank Sector Weight
1 Healthcare 27.6%
2 Technology 15.66%
3 Consumer Discretionary 13.93%
4 Industrials 11.16%
5 Communication Services 8.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVGS icon
876
Navigator Holdings
NVGS
$1.28B
$534K ﹤0.01%
+57,046
New +$596K
ENR icon
877
Energizer
ENR
$1.55B
$531K ﹤0.01%
+13,734
New +$614K
UPWK icon
878
Upwork
UPWK
$1.19B
$531K ﹤0.01%
33,007
+31,044
+1,581% +$535K
PRFT
879
DELISTED
Perficient Inc
PRFT
$529K ﹤0.01%
+15,417
New +$472K
GPRO icon
880
GoPro
GPRO
$126M
$526K ﹤0.01%
+96,293
New +$612K
ACOR
881
DELISTED
Acorda Therapeutics
ACOR
$526K ﹤0.01%
571
+456
+397% +$560K
PRVL
882
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$520K ﹤0.01%
+39,414
New +$574K
APU
883
DELISTED
AmeriGas Partners, L.P.
APU
$514K ﹤0.01%
14,764
-53,002
-78% -$1.86M
MEDP icon
884
Medpace
MEDP
$16.5B
$513K ﹤0.01%
7,842
+2,393
+44% +$138K
EVR icon
885
Evercore
EVR
$11.8B
$511K ﹤0.01%
+5,770
New +$514K
INFY icon
886
Infosys
INFY
$50.7B
$507K ﹤0.01%
47,305
+39,705
+522% +$421K
SPOT icon
887
Spotify
SPOT
$100B
$507K ﹤0.01%
3,467
-20,597
-86% -$2.83M
GLW icon
888
Corning
GLW
$143B
$505K ﹤0.01%
+15,204
New +$488K
SPNT icon
889
SiriusPoint
SPNT
$2.68B
$504K ﹤0.01%
+48,891
New +$523K
GTHX
890
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$503K ﹤0.01%
16,393
+9,773
+148% +$206K
CCOI icon
891
Cogent Communications
CCOI
$508M
$501K ﹤0.01%
+8,433
New +$484K
FSV icon
892
FirstService
FSV
$6.32B
$500K ﹤0.01%
+5,206
New +$471K
VAPO
893
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$498K ﹤0.01%
2,708
+1,688
+165% +$250K
SHAK icon
894
Shake Shack
SHAK
$2.87B
$492K ﹤0.01%
6,815
+5,329
+359% +$329K
RUSHA icon
895
Rush Enterprises Class A
RUSHA
$6.22B
$490K ﹤0.01%
+30,191
New +$528K
EVA
896
DELISTED
Enviva Inc.
EVA
$486K ﹤0.01%
+15,479
New +$491K
CHS
897
DELISTED
Chicos FAS, Inc.
CHS
$480K ﹤0.01%
+142,550
New +$518K
PLUS icon
898
ePlus
PLUS
$2.34B
$478K ﹤0.01%
+13,860
New +$576K
IPG
899
DELISTED
Interpublic Group of Companies
IPG
$473K ﹤0.01%
20,921
-1,882
-8% -$41.8K
SSRM icon
900
SSR Mining
SSRM
$6.48B
$470K ﹤0.01%
34,244
-16,350
-32% -$195K
34 35
36
37 38

Similar funds

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PAM
PFM Asset Management Harrisburg, Pennsylvania $5.36B AUM 21.04% 1-Year Est. Return
HB
Homrich & Berg Atlanta, Georgia $4.47B AUM 22.61% 1-Year Est. Return
MWA
Marshall Wace Asia Central, Hong Kong $4.23B AUM 69.9% 1-Year Est. Return
3SCA
36 South Capital Advisors London, United Kingdom $3.76B AUM
HFCIV
H&F Corporate Investors VII San Francisco, California $3.61B AUM 26.49% 1-Year Est. Return
DVC
Deer VIII & Co Larchmont, New York $3.56B AUM
NAM
NorthCoast Asset Management Greenwich, Connecticut $2.74B AUM 25.44% 1-Year Est. Return

Marshall Wace North America's Q2 2019 Portfolio in Review

As of Q2 2019, Marshall Wace North America held 1,899 positions worth $16.1B, up 14% from $14.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Marshall Wace North America deployed $1.34B of net new capital in Q2 2019, opening 351 new positions and adding to 456 existing holdings. Its largest new stake was Abbott: 1,884,363 shares worth $158M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Pfizer, an estimated $306M trimmed.

  • Marshall Wace North America's largest Q2 2019 buy was Abbott: 1,884,363 shares worth $158M.
  • Marshall Wace North America added most to Meta Platforms (Facebook) in Q2 2019, an estimated $260M increase.
  • Marshall Wace North America's biggest Q2 2019 reduction was Pfizer, cutting an estimated $306M.
  • Marshall Wace North America fully exited UnitedHealth in Q2 2019, selling an estimated $244M.
  • Marshall Wace North America's ten largest holdings make up 19% of its $16.1B portfolio in Q2 2019.
  • Marshall Wace North America opened 351 new positions and closed 805 in Q2 2019.
  • Marshall Wace North America's portfolio value rose 14% quarter-over-quarter to $16.1B.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.